Urinary Bladder Cancer Clinical Trial
— CanMoReOfficial title:
The Effect of Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer - the CanMoRe Study
Verified date | October 2023 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of the CanMoRe study is to evaluate the impact of a standardized and individually adapted exercise intervention in Primary Health Care aiming at improving physical function (primary outcome) and habitual physical activity, health related quality of life, fatigue and psychological well-being in patients undergoing radical cystectomy due to urinary bladder cancer.
Status | Completed |
Enrollment | 100 |
Est. completion date | June 20, 2023 |
Est. primary completion date | November 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients who are planned for a robotic assisted laparoscopic radical cystectomy due to urinary bladder cancer at the Karolinska University Hospital Solna will be included in the trial. The patients should be able to talk and understand Swedish, live in the Stockholm County Council area and be mobile with or without walking aid. Exclusion Criteria: - Patients who will undergo radical cystectomy on a non-curative basis will not be included. |
Country | Name | City | State |
---|---|---|---|
Sweden | Karolinska University Hospital | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet | Karolinska University Hospital |
Sweden,
Porserud A, Karlsson P, Rydwik E, Aly M, Henningsohn L, Nygren-Bonnier M, Hagstromer M. The CanMoRe trial - evaluating the effects of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer: the study protocol of a randomised controlled trial. BMC Cancer. 2020 Aug 26;20(1):805. doi: 10.1186/s12885-020-07140-5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Six-minute walk test | The test reproduces activity of daily living at a sub maximal level. Output: meters Score: 0-900. | Change from baseline to after 12 weeks intervention | |
Secondary | ActivPAL accelerometer | Habitual physical activity, measured for 7 consecutive days. Output: number of steps per day. | Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge | |
Secondary | Chair stand test | Measure of leg strength. Output: Scale 0-30 | Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge | |
Secondary | Hand grip strength | Measure of hand grip strength (Jamar hand dynamometer). Output: Kilo 0-60 | Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge, | |
Secondary | European Organisation for Research and Treatment of Cancer (EORTC) Quality of life for cancer patients QLQ-C30 | Health related quality of life. Output: Scale 0-100. A higher score is worse outcome. For more information see https://qol.eortc.org/questionnaires/ | Measurement 1: Baseline Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge | |
Secondary | EORTC QLQ-BLM30 | Health related quality of life specific for bladder cancer Output: Scale 0-100, a higher score is worse | Measurement 1: Baseline Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge | |
Secondary | Piper Fatigue Scale | Fatigue. Output: Scale 0-10. A higher score is worse, i.e more fatigue | Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge | |
Secondary | Numeric rating scale (NRS) | Pain. Output: Scale 0-10, A higher score is worse i.e more pain | Measurement 1: Baseline, Measurement 2: After 12 weeks intervention. Measurement 3: 1 year after discharge | |
Secondary | Hospital Anxiety and Depression Scale (HADS) | Psychological wellbeing. Output: Scale 0-21. A higher score is worse | Measurement 1: Baseline, Measurement 2: 12 weeks. Measurement 3: 1 year after discharge | |
Secondary | Readmission | Readmissions to hospital. Output: Yes/No | Collected from journals using standardized time frames at 30 and 90 days | |
Secondary | Complications | Complications such as Pneumonia Output: according to Clavien - Dindo classification | Collected from journals using standardized time frames at 30 and 90 days | |
Secondary | Six-minute walk test | The test reproduces activity of daily living at a sub maximal level. Output: meters Score: 0-900. | Measurement 3: 1 year after discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00872495 -
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
|
||
Withdrawn |
NCT05335707 -
Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
|
||
Not yet recruiting |
NCT04525781 -
Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
|
||
Completed |
NCT02897765 -
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT05822934 -
Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer
|
Phase 3 | |
Completed |
NCT06156787 -
Patterns of Urinary Bladder Cancer in Darfur, Suda
|
||
Completed |
NCT02722538 -
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
|
Phase 1 | |
Completed |
NCT02437539 -
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 1 | |
Completed |
NCT02139371 -
Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
|
Phase 0 | |
Completed |
NCT03433924 -
An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
|
||
Active, not recruiting |
NCT03132922 -
MAGE-A4ᶜ¹º³²T for Multi-Tumor
|
Phase 1 | |
Completed |
NCT05946369 -
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
|
||
Completed |
NCT00462488 -
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
|
Phase 2 | |
Recruiting |
NCT05621837 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
||
Recruiting |
NCT05644041 -
Intravesical Gemcitabine in Patients With NMIBC
|
Phase 2 | |
Completed |
NCT04635566 -
Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute
|
N/A | |
Recruiting |
NCT04861584 -
Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
|
Phase 2 | |
Completed |
NCT01836978 -
Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy
|
N/A | |
Terminated |
NCT01374789 -
PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
|
Phase 2 | |
Recruiting |
NCT03844256 -
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
|
Phase 1/Phase 2 |